What is Apo-Methylphenidate ER used for?

Apo-Methylphenidate ER is indicated for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.

Who makes Apo-Methylphenidate ER?

Apo-Methylphenidate ER is developed by The Royal Ottawa Mental Health Centre.

What development phase is Apo-Methylphenidate ER in?

Apo-Methylphenidate ER is in Phase 2.

What are the side effects of Apo-Methylphenidate ER?

Common side effects include Insomnia, Decreased appetite, Headache, Nervousness or anxiety, Tachycardia, Elevated blood pressure.

Last reviewed 2026-04-23 · How we verify

Apo-Methylphenidate ER

The Royal Ottawa Mental Health Centre · Phase 2 active Small molecule

Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the synapse.

Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the synapse. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.

At a glance

Generic name	Apo-Methylphenidate ER
Sponsor	The Royal Ottawa Mental Health Centre
Drug class	Sympathomimetic amine; central nervous system stimulant
Target	Dopamine transporter (DAT); Norepinephrine transporter (NET)
Modality	Small molecule
Therapeutic area	Psychiatry / Neurology
Phase	Phase 2

Mechanism of action

Methylphenidate inhibits the reuptake of dopamine and norepinephrine by blocking their respective transporters (DAT and NET), leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control. The extended-release (ER) formulation provides sustained drug delivery over an extended period.

Approved indications

Attention-deficit/hyperactivity disorder (ADHD)
Narcolepsy

Common side effects

Insomnia
Decreased appetite
Headache
Nervousness or anxiety
Tachycardia
Elevated blood pressure
Abdominal pain

Key clinical trials

Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Apo-Methylphenidate ER CI brief — competitive landscape report
Apo-Methylphenidate ER updates RSS · CI watch RSS
The Royal Ottawa Mental Health Centre portfolio CI